poisar

Stocks · News reference

Jupiter Neurosciences Enters Definitive License Agreement With PharmAla For Its Patented, Non-Racemic MDMA Formulation ALA-002

BenzingaAug 21, 2026, 11:08 AMBenzinga Newsdesk

Two developments have since materially changed the context for that structure. First, on July 20, 2026, PharmAla executed a definitive license agreement granting Jupiter Neurosciences, Inc. (NASDAQ:JUNS) exclusive U.S.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 21, 2026, 11:08 AM
Checked
Aug 21, 2026, 11:08 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARAug 27, 2026, 10:30 AMSEC EDGAR

    8-K filing — JUPITER NEUROSCIENCES, INC. (JUNS)

    Filed: 2026-08-27 AccNo: 0001493152-26-040308 Size: 323 KB Item 1.01: Entry into a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    Read original at edgar